Standard BioTools Inc. LAB NASDAQ

Standard BioTools Inc. (LAB) has shown moderate revenue growth over the past 3 years, expanding from $98M to $85M (average +7.2%/yr). The company reported a net loss of $75M in its most recent fiscal year, with earnings trending at 6.9%/yr. The net profit margin is -87.8%, which is negative. The company has not reported a profit in any of the last 4 years tracked. The gross margin is 49.9% (moderate), with a +12.1pp trend over the period. With a market cap data available and MOAT composite score of 43/100, the company has a low competitive position.

Criteria proven by this page:

• GROWTH (65/100, Pass) — proving strong growth momentum
• PAST (0/100, Fail) — the company has frequently reported losses. Looking at the full 21-year history, the company was profitable in 0 of 21 years — a mixed long-term record
• INCOME (10/100, Fail) — the company is currently operating at a loss
• MOAT (43/100, Fail) — limited competitive moat based on margins and scale

Overall SharesGrow Score: 51/100 with 3/7 criteria passed.